- Home
- TXMD vs CRVO Comparison
TXMD vs CRVO Comparison
Compare TXMD & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | CRVO |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 21.5M |
| IPO Year | 2012 | 2011 |
Fundamental Metrics
Financial Performance| Metric | TXMD | CRVO |
|---|---|---|
| Price | $1.74 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.80 |
| AVG Volume (30 Days) | 18.6K | ★ 324.3K |
| Earning Date | 11-24-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $1,761,000.00 | ★ $4,006,510.00 |
| Revenue This Year | $207.74 | N/A |
| Revenue Next Year | $2.15 | N/A |
| P/E Ratio | $84.50 | ★ N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $1.43 | $1.27 |
| 52 Week High | $2.95 | $10.00 |
Technical Indicators
Market Signals| Indicator | TXMD | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 21.87 |
| Support Level | N/A | N/A |
| Resistance Level | $2.16 | $3.86 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 45.28 | 6.48 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.